IP Library Granted Patent US 8,764,733
Granted Patent B2
US 8,764,733 · App. 13/538,852 · Granted Jul 1, 2014

Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,764,733
App. No.
13/538,852
Granted
Jul 1, 2014
Kind
B2
Abstract

Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.

Claims (23)

1. A therapeutic preparation comprising vasopressin or a peptide vasopressin analogue, the preparation shaped as a solid tissue penetrating member shaped and configured to penetrate and be inserted into an intestinal wall after oral ingestion, wherein upon insertion, the preparation releases vasopressin or a peptide vasopressin analog into the blood stream from the intestinal wall, the tissue penetrating member having a proximal and distal portion, the proximal portion configured to be detachably coupled to an advancement means disposed in a swallowable capsule.

2. The preparation of claim 1 , wherein the preparation is adapted for insertion into the wall of the small intestine.

3. The preparation of claim 1 , wherein the advancement means comprises a piston or a plunger.

4. The preparation of claim 1 , wherein all of the preparation is in solid form.

5. The preparation of claim 1 , wherein the preparation is adapted to be orally delivered in a swallowable capsule.

6. The preparation of claim 5 , wherein the preparation is adapted to be operably coupled to delivery means having a first configuration and a second configuration, the preparation being contained within the capsule in the first configuration and advanced out of the capsule and into the intestinal wall in the second configuration.

7. The preparation of claim 6 , wherein the delivery means comprises a least one expandable balloon having an expanded and a non-expanded state and the first configuration is the non-expanded state and the second configuration is the expanded state.

8. The preparation of claim 1 , wherein the preparation comprises a biodegradable material which degrades within the intestinal wall to release vasopressin or a peptide vasopressin analogue into the blood stream.

9. The preparation of claim 8 , wherein the biodegradable material comprises PGLA, a sugar or maltose.

10. The preparation of claim 1 , wherein the preparation comprises at least one pharmaceutical excipient.

11. The preparation of claim 10 , wherein the at least one pharmaceutical excipient comprises at least one of a binder, a preservative or a disintegrant.

12. The preparation of claim 11 , wherein the binder comprises PEG.

13. The preparation of claim 1 , wherein the tissue penetrating member comprises a biodegradable material which degrades within the intestinal wall to release vasopressin or a peptide vasopressin analogue into the blood stream.

14. The preparation of claim 13 , wherein the biodegradable material comprises maltose or PGLA.

15. The preparation of claim 1 , wherein a eight percent of vasopressin or peptide vasopressin analogue in the tissue penetrating member comprises between about 0.1 to 1%.

16. The preparation of claim 1 , wherein the tissue penetrating member includes a retaining feature for retaining the tissue penetrating member within the intestinal wall after insertion.

17. The preparation of claim 16 , wherein the retaining feature comprises at least one of a barb or an inverse taper shape of the tissue penetrating member.

18. The preparation of claim 1 , wherein tissue penetrating member includes a shaped section in which the vasopressin or peptide vasopressin analogue is contained.

19. The preparation of claim 18 , wherein the shaped section has a cylinder or pellet shape.

20. The preparation of claim 1 , wherein the tissue penetrating member has sufficient stiffness to be advanced completely into the intestinal wall by the application of a force to the tissue penetrating member.

21. The preparation of claim 1 , wherein the preparation is configured to produce a long-term release of vasopressin or peptide vasopressin analogue.

22. The preparation of claim 21 , wherein the preparation is configured produce a long-term release of vasopressin or peptide vasopressin analogue to produce a selectable t 1/2 .

23. The preparation of claim 22 , wherein the t 1/2 is about 10 hours.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 19, 2025
From: AVENUE VENTURE OPPORTUNITIES FUND, L.P.
To: RANI THERAPEUTICS, LLC
Reel/Frame 073971/0117 →
SECURITY INTEREST Recorded Aug 9, 2022
From: RANI THERAPEUTICS, LLC
To: AVENUE VENTURE OPPORTUNITIES FUND, L.P., AS AGENT
Reel/Frame 061131/0478 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2013
From: IMRAN, MIR
To: RANI THERAPEUTICS, LLC
Reel/Frame 030731/0187 →